Engineering Promoters for Specific Antigen Expression in a Synthetic DNA Vaccine Construct

点击翻译按钮获取中文摘要

The collaboration between Synpromics Ltd. and Touchlight Genetics Ltd. will combine two highly innovative and complementary technology platforms to develop an improved approach to developing DNA vaccines. The project will leverage Synpromics's proprietary technology to rationally design synthetic promoters that drive cell-specific antigen expression and that enhance the effectiveness of Touchlight Genetics’s unique synthetic DNA vaccine cassette platform. The resulting new technology will subsequently be applied by Touchlight Genetics in the company’s internal DNA vaccine develoment programs, as well as be available for licensing by other developers. The project is expected to establish a unique UK-based synthetic biology capability for the production of safer and more effective DNA-based medicines.